Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults

Journal of Infectious Diseases

Volumn 181, Issue 4, 2000, Pages 1471-1474

  Boivin, Guy ^c   Goyette, Nathalie ^d   Hardy, Isabelle ^d   Aoki, Fred ^a   Wagner, Anthony ^b   Trottier, Sylvie ^d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Glaxo Wellcome Inc   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ZANAMIVIR;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; INFLUENZA; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; SYMPTOMATOLOGY; THROAT CULTURE; TREATMENT OUTCOME; VIRUS LOAD;

ADMINISTRATION, INHALATION; ADULT; ANTIVIRAL AGENTS; CANADA; ENZYME INHIBITORS; GUANIDINES; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; PYRANS; SIALIC ACIDS; ZANAMIVIR;

EID: 0005849036     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315392     Document Type: Article

References (15)

1. 1. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26:1418-24.
2. 2. von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363:418-23.
3. 3. Woods JM, Bethell RC, Coates JA, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37:1473-9.
4. 4. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997; 337:874-80.
5. 5. MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in the treatment of influenza virus infections. Lancet 1998; 352: 1877-81.
6. 6. Ellis JS, Fleming DM, Zambon MC. Multiplex reverse transcription PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996. J Clin Microbiol 1997; 35:2076-82.
7. 7. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997; 71:3385-90.
8. 8. Xu X, Cox NJ, Bender CA, Regnery HL, Shaw MW. Genetic variation in neuraminidase genes of influenza A (H3N2) viruses. Virology 1996; 224: 175-83.
9. 9. Fitch WM, Bush RM, Bender CA, Cox NJ. Long term trends in the evolution of H(3) HA1 human influenza type A. Proc Natl Acad Sci USA 1997; 94:7712-8.
10. 10. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest 1998; 101:643-9.
11. 11. Newman SP, Brown J, Pickford M, Fayinka S, Cass L. Deposition pattern in the respiratory tract of the neuraminidase inhibitor zanamivir: a gamma scintigraphic study [abstract H-134]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997.
12. 12. Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996; 70:1818-27.
13. 13. Staschke KA, Colacino JM, Baxter AJ, et al. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 1995; 214: 642-6.
14. 14. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178:1257-62.
15. 15. Barnett J, Dempsey M, Tisdale M, Rothbarth PH, De Groot R, Osterhaus ADME. Susceptibility monitoring of influenza virus clinical isolates to the neuraminidase inhibitor zanamivir (GG167) during phase II clinical efficacy trials [abstract H-093]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997.